Greetings and welcome to the Xtant Medical Fourth Quarter and Full Year 2018 Results Conference Call. At this time, all participants are in a listen-only mode. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Mr. David Carey. Please go ahead.

Thank you, operator. And welcome to Xtant Medical’s fourth quarter and full year 2018 financial results call. Joining me today for the conference call will be Greg Jensen, Vice President, Finance and Interim Chief Financial Officer. Today's call is being webcast and will be posted on the Company's website for playback. During the course of this call, management may make certain forward-looking statements regarding future events and the Company's expected future performance. These forward-looking statements reflect Xtant's current perspective on existing trends and information, and can be identified by such words as expect, plan, will, may, anticipate, believe, should, intend, and other words with similar meaning. Any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, including those noted in the Risk Factors section of the company’s annual report on Form 10-K that will be filed today. Actual results may differ materially. The company’s financial results, press release, and today’s discussion includes certain non-GAAP financial measures. Please refer to the non-GAAP to GAAP reconciliations, which appears in the tables of our press release and are otherwise available on our website. Note that our Form 8-K filed with our financial release press release provides a detailed narrative that describes our use of such measures. For the benefit of those of you who may be listening to the replay, this call was held and recorded on Monday, April 1, at approximately 09:00 AM Eastern Time. Since then, the Company may have made additional announcements related to the topics discussed herein. Please reference the Company's most recent press releases and filings with the SEC. The Company declines any obligation to update these forward-looking statements except as required by applicable law. Now, I'd like to turn the call back over to Greg Jenson.

Thank you, David. And good morning to everyone listening. I will begin by providing a general update of Xtant, followed by a review of our financial results for the fourth quarter and full year 2018. Let me start by saying that I joined Xtant almost two months ago, because I believed that the company has tremendous value to offer to both patients and shareholders .Xtant’s portfolio of orthobiologics and spinal fixation systems are important solutions for the challenges of spinal fusion in complex spine, deformity, and degenerative procedures. I also have great confidence that the recent hires that we have made within our sales team gives us the expertise and leadership needed to realize the commercial and clinical value of these products. As announced in February, we added to our team five senior sales executives comprising of a Vice-President of U.S sales and four regional Vice-Presidents. Combined, these very talented individuals have over 120 years of proven experience in sales with the majority of expertise coming from sales within the spine industry. Their deep relationships in the commercial spine market and their extended knowledge of spine products and therapies are enabling us to take our sales strategy and execution to a level that we have not previously achieved, and while it will take time to be reflected in our financial results, the value they provide to Xtant is already quite clear to our customers and within the company. Under the leadership of Kevin Brandt, who joined Xtant last July as Chief Commercial Officer, this newly revitalized sales force has the strategy, motivation, and dedication to help Xtant grow our revenue through increasing sales of our diverse product portfolio. Ensuring the success of our sales efforts requires that we offer customers products that meet their needs and the needs of their…

This concludes today’s teleconference. Thank you for your participation. You may disconnect your lines at this time.